Noopur Raje, MD
Facon T et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380(22):2104-15. Abstract
Kapoor P et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2013;31(36):4529-35. Abstract
Moreau P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomized, open-label, phase 3 study. Lancet 2019;394(10192):29-38. Abstract
Moreau P et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. ASCO 2019;Abstract 8003.
Perrot A et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 2018;132(23):2456-64. Abstract
Voorhees P et al. Daratumumab + lenalidomide, bortezomib & dexamethasone improves depth of response in transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Proc IMW 2019;Abstract OAB-87.
Nikhil C Munshi, MD
Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782-91. Abstract
Dimopoulous MA et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomized, placebo-controlled phase 3 trial. Lancet 2019;393(10168):253-64. Abstract
McCarthy PL et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. J Clin Oncol 2017;35:3279–89. Abstract
McCarthy PL et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1770-81. Abstract
Munshi NC et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis. JAMA Oncol 2017;3(1):28-35. Abstract
Palumbo A et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371(10):895-905. Abstract
Palumbo A et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data. Lancet Oncol 2014;15(3):333-42. Abstract
Perrot A et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 2018;132(23):2456-64. Abstract
María-Victoria Mateos, MD, PhD
Barbee MS et al. Subcutaneous versus intravenous bortezomib: Efficiency practice variables and patient preferences. Ann Pharmacother 2013;47(9):1136-42. Abstract
Chari A et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381(8):727-38. Abstract
Chng WJ et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia 2016;30(5):1071-8. Abstract
Costa LJ et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Proc ASH 2018;Abstract 303.
Dimopoulos MA et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379(19):1811-22. Abstract
Dimopoulos MA et al. Pomalidomide + bortezomib + low-dose dexamethasone vs bortezomib + low-dose dexamethasone as second-line treatment in patients with lenalidomide-pretreated multiple myeloma: A subgroup analysis of the phase 3 OPTIMISMM trial. Proc ASH 2018;Abstract 3278.
Dimopoulos MA et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomized, phase 3, open-label, multicenter study. Lancet Oncol 2016;17(1):27-38. Abstract
Dimopoulos MA et al. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev 2015;41(10):827-35. Abstract
Faiman BM et al; The International Myeloma Foundation Nurse Leadership Board. Renal complications in multiple myeloma and related disorders: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs 2011;15(Suppl):66-76. Abstract
Greipp PR et al. International staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412-20. Abstract
Handforth C et al. The prevalence and outcomes of frailty in older cancer patients: A systematic review. Ann Oncol 2015;26(6):1091-101. Abstract
Mateos MV et al. Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma: COLUMBA. EHA 2019;Abstract S823.
Mateos MV et al. Efficacy and safety of carfilzomib and dexamethasone in lenalidomide exposed and refractory multiple myeloma patients: Combined analysis of carfilzomib trials. Proc ASH 2018;Abstract 1963.
Mateos MV et al. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients: Two-year update of CASTOR. Proc ASH 2018;Abstract 3270.
Miceli TS et al; International Myeloma Foundation Nurse Leadership Board. Maintaining bone health in patients with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs 2011;15(Suppl):9-23. Abstract
Moreau P et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): Interim analysis results of a randomized, phase 3 study. Lancet Oncol 2018;19(7):953-64. Abstract
Moreau P et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia 2017;31(1):115-22. Abstract
Moreau P et al; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):52-61. Abstract
Ramsenthaler C et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: A multi-center study. BMC Cancer 2016;16:427. Abstract
Richardson PG et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomized, open-label, phase 3 trial. Lancet Oncol 2019;20(6):781-94. Abstract
Richardson PG et al. OPTIMISMM: Phase 3 trial of pomalidomide, bortezomib, and low-dose dexamethasone vs bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed/refractory multiple myeloma. EHA 2018;Abstract S847.
Siegel DS et al. Pomalidomide + low-dose dexamethasone + daratumumab in relapsed and/or refractory multiple myeloma after lenalidomide-based treatment failure. Proc ASH 2018;Abstract 3271.
Sonneveld P et al. Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide. The EMN011 trial. Proc ASH 2018;Abstract 801.
Sonneveld P et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia 2013;27(10):1959-69. Abstract
Tariman JD et al. Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma. Cancer Treat Commun 2014;2(2-3):34-47. Abstract
Usmani SZ et al. Efficacy of daratumumab in combination with standard of care regimens in lenalidomide-exposed or -refractory patients with relapsed/refractory multiple myeloma (RRMM): Analysis of the CASTOR, POLLUX, and MMY1001 Studies. Proc ASH 2018;Abstract 3288.
Sagar Lonial, MD
Attal M et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet 2019;394(10214):2096-107. Abstract
Kaufman J et al. Venetoclax monotherapy and combined with dexamethasone as targeted therapy for relapsed/refractory T(11;14) multiple myeloma. EHA 2018;Abstract PS1317.
Kumar S et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. EHA 2019;Abstract LB2601.
Kumar S et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130(22):2401-9. Abstract
Lonial S et al. First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2019;Abstract 8006.
Matulis SM et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 2016;30(5):1086-93. Abstract
Matyskiela ME et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem 2018;61:535-42. Abstract
Moreau P et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood 2017;130(22):2392-400. Abstract
Ponder KG et al. Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer Biol Ther 2016;17(7):769-77. Abstract
Richardson PG et al. A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2019;Abstract 8004.
Richardson PG et al. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol 2018;14:1035-47. Abstract
Richardson PG et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609-17. Abstract
Souers AJ et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202-8. Abstract
Touzeau C et al. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia 2018;32(9):1899-907. Abstract
van de Donk NWCJ et al. CD38 antibodies in multiple myeloma: Back to the future. Blood 2018;131(1):13-29. Abstract
Jesús G Berdeja, MD
Berdeja JG et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy. Proc ASH 2019;Abstract 927.
Cooper D et al. Safety and preliminary clinical activity of REGN5458, an anti-BCMA x anti-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Proc ASH 2019;Abstract 3176.
Costa LJ et al. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Interim results of a phase 1 multicenter trial. Proc ASH 2019;Abstract 143.
Cowan AJ et al. Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma. Proc ASH 2019;Abstract 204.
Garfall AL et al. Combination anti-BCMA and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma. Proc ASH 2019;Abstract 1863.
Gregory T et al. Efficacy and safety of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM). Proc ASH 2018;Abstract 1012.
Li C et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 for relapsed/refractory multiple myeloma: Updated results from a phase 1 dose-climbing trial. Proc ASH 2019;Abstract 930.
Li C et al. Efficacy and safety of fully human BCMA targeting CAR T cell therapy in relapsed/refractory multiple myeloma. Proc ASH 2019;Abstract 582.
Madduri D et al. Results from CARTITUDE-1: A phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Proc ASH 2019;Abstract 577.
Mailankody S et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Initial proof of concept results from a Phase 1/2/multicenter study. Proc ASH 2018;Abstract 957.
Njau MN, Jacob J. Inducible nitric oxide synthase is crucial for plasma cell survival. Nat Immunol 2014;15(3):219-21. Abstract
Raje N et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019;380(18):1726-37. Abstract
Shah N et al. Initial results from a phase 1 clinical study of bb21217, a next-generation anti BCMA CAR T therapy. Proc ASH 2018;Abstract 488.
Tai YT et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014;123(20):3128-38. Abstract
Topp MS et al. Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study. ASCO 2019;Abstract 8007.
Trudel S et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study. Blood Cancer J 2019;9(4):37. Abstract
Trudel S et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial. Lancet Oncol 2018;19(12):1641-53. Abstract
Wang BY et al. Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Proc ASH 2019;Abstract 579.
Yan L et al. Sequential CD19- and BCMA-specific chimeric antigen receptor T cell treatment for RRMM: Report from a single center study. Proc ASH 2019;Abstract 578.
Zhao WH et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Onc 2018;11(1):141. Abstract
Robert Z Orlowski, PhD, MD
Kumar S et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30(9):989-95. Abstract
Nuvolone M, Merlini G. Systemic amyloidosis: Novel therapies and role of biomarkers. Nephrol Dial Transplant 2017;32(5):770-80. Abstract
Spinner MA et al. Novel approaches in Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2018;32(5):875-90. Abstract
Treon SP et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015;372(15):1430-40. Abstract
Treon SP et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 2012;367(9):826-33. Abstract
Treon SP. How I treat Waldenström macroglobulinemia. Blood 2009;114(12):2375-85. Abstract
Wechalekar AD et al. Systemic amyloidosis. Lancet 2016;387(10038):2641-54. Abstract